Medication info
Telpinstar Tablet 80/5 mg

Telpinstar Tablet 80/5 mg

Prescription medicationOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
Biconvex oval double layer tablet in white and light blue color
Packaging
Tablet/PTP - 30 tablets/PTP [(10 tablets/PTP × 3)]
Approval status
Active

MFDS item code 201605809 · Approved 2016.09.30 · Insurance code 642003990

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual components (telmisartan or amlodipine). However, if blood pressure is not controlled with the individual components as described below, switching directly to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. ○ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine dosage is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients Requiring Caution in Administration’). In elderly patients aged 75 years or older, clearance of amlodipine is reduced; therefore, treatment should be started at a low dose and the dose increased gradually.
Child dose
The safety and efficacy of this drug have not been established in pediatric patients 18 years of age or younger; administration is not recommended.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with telmisartan or amlodipine.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose using the individual components (telmisartan or amlodipine). However, if blood pressure is not controlled with the individual components as described below, switching directly to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. ○ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine dosage is recommended for elderly patients, but caution should be exercised when increasing the dose (see section ‘3. Patients Requiring Caution in Administration’). In elderly patients aged 75 years or older, clearance of amlodipine is reduced; therefore, treatment should be started at a low dose and the dose increased gradually.

Child dose

The safety and efficacy of this drug have not been established in pediatric patients 18 years of age or younger; administration is not recommended.

Precautions

This medication should not be used during pregnancy, especially in the second and third trimesters, as it can cause serious harm to the fetus. If this medication is taken during pregnancy, it should be discontinued as soon as possible, and if necessary, replaced with another safe medication. This medication should not be administered to patients with certain diseases, such as those with severe liver or heart conditions, women of childbearing potential, or nursing mothers. Additionally, caution is needed when using this medication in specific patient groups, such as patients with impaired liver function, kidney disease, the elderly, and patients with heart valve disease. Side effects such as dizziness and peripheral edema may occur when taking this medication, so consult a healthcare professional if any unusual symptoms arise. Symptoms of hypotension may occur, so if symptoms are present, lie down immediately and seek treatment at a hospital if necessary. This medication can cause hyperkalemia, so potassium levels in the blood should be monitored regularly. Patients with decreased kidney function should periodically check kidney function and electrolyte levels while taking this medication. This medication can interact with other drugs, so inform your healthcare provider of any other medications you are taking, especially lithium, digoxin, warfarin, and non-steroidal anti-inflammatory drugs. It is advisable not to use this medication while breastfeeding, and caution should be exercised when driving or operating machinery as dizziness or drowsiness may occur. In case of overdose, symptoms such as hypotension, dizziness, and heart abnormalities may occur, so compliance with the prescribed dosage is crucial, and if any unusual symptoms arise, visit a medical facility immediately. Safety and efficacy have not been adequately established in pediatric patients, so this medication is not recommended for children. This medication should be stored out of the reach of children and taken out of the sealed packaging immediately before use.

Side effects

  • dizziness
  • peripheral edema
  • syncope
  • upper respiratory infection
  • pharyngitis
  • sinusitis
  • urinary tract infection
  • cystitis
  • sepsis
  • anemia
Show 101 more
  • thrombocytopenia
  • eosinophilia
  • leukopenia
  • hypersensitivity
  • anaphylactic reaction
  • hyperkalemia
  • hypoglycemia
  • hyponatremia
  • hyperglycemia
  • depression
  • insomnia
  • mood changes
  • anxiety
  • confusion
  • drowsiness
  • headache
  • migraine
  • paresthesia
  • sensory loss
  • dysgeusia
  • tremor
  • extrapyramidal disorder
  • muscular hypertonia
  • visual impairment
  • diplopia
  • vertigo
  • tinnitus
  • palpitations
  • bradycardia
  • tachycardia
  • myocardial infarction
  • ventricular tachycardia
  • arrhythmia
  • atrial fibrillation
  • flushing
  • hypotension
  • orthostatic hypotension
  • vasculitis
  • cough
  • shortness of breath
  • rhinitis
  • changes in bowel habits
  • diarrhea
  • constipation
  • abdominal pain
  • dyspepsia
  • nausea
  • vomiting
  • dry mouth
  • gingival hyperplasia
  • abdominal discomfort
  • pancreatitis
  • gastritis
  • liver function abnormality
  • liver disorder
  • hepatitis
  • jaundice
  • elevated liver enzymes
  • pruritus
  • sweating
  • rash
  • hair loss
  • purpura
  • skin discoloration
  • eczema
  • erythema
  • angioedema
  • toxic skin rash
  • drug rash
  • urticaria
  • erythema multiforme
  • exfoliative dermatitis
  • Stevens-Johnson syndrome
  • photosensitivity
  • arthralgia
  • muscle cramps
  • joint pain
  • myalgia
  • back pain
  • limb pain
  • tendon pain
  • renal dysfunction
  • acute renal failure
  • urination disorders
  • polyuria
  • nocturia
  • erectile dysfunction
  • gynecomastia
  • edema
  • asthenia
  • fatigue
  • chest pain
  • malaise
  • influenza-like illness
  • elevated liver enzymes
  • increased blood creatinine
  • weight gain
  • weight loss
  • increased blood uric acid
  • increased blood creatine phosphokinase
  • decreased hemoglobin

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not allow light in, and should be kept at room temperature between 1 degree and 30 degrees. Storing it this way helps maintain the medication's effectiveness and prevent degradation.

Appearance and packaging

Appearance

Biconvex oval double layer tablet in white and light blue color

Package unit

Tablet/PTP - 30 tablets/PTP [(10 tablets/PTP × 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.